Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Dallas, TX (June 13, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya will give a Company overview and a clinical update on the Company’s pipeline during the BIO International Convention, being held June 13-16, 2022, in San Diego, CA. The presentation, titled “Pioneering A New Wave of Optogenetic Therapeutics for Vision Restoration,” will take place on June 14, at 4:15 PM PT in Company Presentation Theater 3.

“We will highlight our Multi-Characteristic Opsin gene therapy candidate, MCO-010, which is part of our optogenetics platform for vision restoration in people blinded by retinitis pigmentosa and other retinal diseases,” said Ms. Bhattacharya.

“This is an exciting time for the Company as we advance our clinical programs and expect multiple clinical milestones for MCO-010 over the next 12-months. In the first quarter of 2023, we anticipate reporting both topline Phase 2b RESTORE data results for MCO-010 in patients with retinitis pigmentosa, as well as 6-month data from our open label Phase 2 STARLIGHT trial for patients with Stargardt disease,” continued Ms. Bhattacharya.

Ms. Bhattacharya presently serves on the board of directors of BIO.  She is also a member of the BIO sub-committee for capital formation, advocating for public policy beneficial to small cap and private biotech companies. She will be involved in BIO Board of Directors activities throughout the week.  Additionally, Nanoscope executive team members will be available for meetings to discuss partnering and strategic opportunities.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners

PR Contact:
Dan Eramian
Opus Biotech Communications

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.